Clinical characteristics were comparable between elderly primary ITP patients with and without TGFBR2 variants, although heterozygote carriers demonstrated an elevated rate to achieve PR (83.3% vs. 31.6%, p = 0.016) after first-line regimens (Table 3). The gene discussed is TGFBR2; the disease is autoimmune thrombocytopenic purpura.